Cagrilintide vs Tirzepatide
Amylin pathway vs incretin pathway.
| Attribute | Cagrilintide Long-acting amylin analog | Tirzepatide Dual GIP/GLP-1 receptor agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Satiety and amylin pathway research | Dual-agonist weight loss research |
| In plain English | Amylin is a hormone released with insulin that tells your brain you're full. Cagrilintide mimics it on a long schedule. | Tirzepatide is like semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies. |
| How it works | Activates amylin receptors, slowing gastric emptying and reducing food intake via the area postrema in the brain. | Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying. |
| Researchers study | Body weight reduction alone and combined with semaglutide (CagriSema). | Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes. |
| Internet discussion | Discussed as the secret to lifting GLP-1 weight loss plateaus. | Often described as 'semaglutide on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules. |
Cagrilintide
Satiety and amylin pathway research
Amylin is a hormone released with insulin that tells your brain you're full. Cagrilintide mimics it on a long schedule.
Activates amylin receptors, slowing gastric emptying and reducing food intake via the area postrema in the brain.
Body weight reduction alone and combined with semaglutide (CagriSema).
Discussed as the secret to lifting GLP-1 weight loss plateaus.
Cagrilintide is a long-acting amylin analog studied as an add-on to GLP-1 agonists for additional satiety and weight loss.
Tirzepatide
Dual-agonist weight loss research
Tirzepatide is like semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies.
Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying.
Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes.
Often described as 'semaglutide on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules.
Tirzepatide is a dual GLP-1/GIP agonist with strong clinical data for weight reduction and glycemic control.